Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Gefitinib is a targeted therapy for non-small cell lung cancer, primarily effective when the epidermal growth factor receptor (EGFR) gene is mutated.
• Tumor heterogeneity, the presence of different cell populations within a tumor, is increasingly recognized in cancer.

Observation:

• A case of lung adenocarcinoma presented with distinct EGFR gene statuses in primary and metastatic sites.
• The primary lung tumor harbored a mutant-type EGFR gene, while metastatic bone lesions showed a wild-type EGFR gene.

Findings:

• This heterogeneity in EGFR gene status within a single patient led to differential responses to gefitinib therapy.
• The coexpression of mutant and wild-type EGFR genes in different tumor sites suggests the presence of at least two distinct tumor cell populations.

Implications:

• This case highlights tumor genetic heterogeneity as a potential mechanism for acquired resistance to EGFR-targeted therapies like gefitinib.
• Understanding such heterogeneity is crucial for developing effective treatment strategies for lung adenocarcinoma and other cancers.